Dental Drug Promises to Regenerate Human Teeth

JAPAN: A groundbreaking drug that could potentially enable humans to regrow their teeth is set to enter its first clinical trial phase later this year, according to a report published on Japan Times.

Promising Results from Animal Studies

The drug, developed by researchers at Kyoto University Hospital, has shown promising results in initial tests on animals. Ferrets and mice treated with the experimental medication successfully grew new teeth without any significant side effects.

Dr. Katsu Takahashi, the lead researcher and head of dentistry and oral surgery at Kitano Hospital, expressed enthusiasm for the project’s potential impact:

“We want to do something to help those who are suffering from tooth loss or absence. While there has been no treatment to date providing a permanent cure, we feel that people’s expectations for tooth growth are high.”

New gel could stimulate bone regeneration

Targeting a Key Protein for Tooth Regeneration

The drug works by deactivating the uterine sensitisation-associated gene-1 (USAG-1) protein, which suppresses tooth growth. By blocking the interaction between USAG-1 and other proteins, the treatment triggers bone morphogenetic protein (BMP) signaling, leading to the generation of new bone and, potentially, new teeth.

Researchers noted the promising similarities between humans and the test animals, stating, “The USAG-1 protein has a high amino acid homology of 97 percent between different animal species, including humans, mice, and beagles.”

Human Clinical Trials on the Horizon

The first human trial of the drug is scheduled to take place at Kyoto University Hospital from September 2024 to August 2025. The trial will involve 30 male participants aged 30 to 64 who are missing at least one molar. Researchers aim to assess the treatment’s effectiveness on human dentition.

Potential for Widespread Application

If the clinical trials prove successful, the researchers envision a future where the drug could be commercially available by 2030, potentially eliminating the need for dentures and other dental prosthetics.

Further trials are planned to evaluate the drug’s efficacy in treating congenital tooth deficiencies in children aged 2 to 7, as well as partial edentulism (missing one to five adult teeth) in older adults.

While the conditions targeted by the drug are relatively rare, the potential impact of a treatment that can regenerate human teeth could be far-reaching and transformative for dental care.